Inmazeb Market Report 2026

Inmazeb Market Overview

• The Inmazeb market growth in the historic period has been driven by past ebola outbreaks, high mortality rates • Market expansion is supported by ongoing outbreak preparedness, expansion of infectious disease funding • Growth Driver: Surge In Ebola Cases Prompts Greater Reliance On Inmazeb For Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Inmazeb Market?

Inmazeb is the brand name for a combination monoclonal antibody therapy (atoltivimab, maftivimab, and odesivimab-ebgn) used to treat Zaire ebolavirus infection (commonly known as Ebola virus disease). The medication works by targeting the Ebola virus glycoprotein, neutralizing the virus, and preventing it from infecting cells. Using a combination of three antibodies, Inmazeb provides robust protection against the virus and helps the immune system combat the infection. The main applications of inmazeb are Ebola virus disease treatment and post-exposure prophylaxis. Ebola Virus Disease Treatment refers to medical interventions aimed at managing symptoms, supporting recovery, and reducing mortality in patients infected with the Ebola virus. This offers treatment of various patient demographics such as pediatric patients, adult patients, and high-risk groups. Inmazeb is distributed by various channels such as hospitals, specialty clinics, and public health programs.

What Is The Inmazeb Market Growth Forecast?

The growth in the forecast period can be attributed to ongoing outbreak preparedness, expansion of infectious disease funding, improved surveillance systems, international health collaborations, investment in antiviral biologics. Major trends in the forecast period include rising demand for ebola therapeutics, government stockpiling of outbreak treatments, focus on combination antibody therapies, rapid deployment in emergency settings, strengthening global health preparedness.

What Are The Drivers Of The Inmazeb Market?

An increasing incidence of ebola outbreaks is expected to propel the growth of the inmazeb market going forward. Ebola virus disease (EVD) is a severe illness caused by ebolaviruses, characterized by transmission from infected animals to humans and subsequent human-to-human spread. The increasing incidence of Ebola can be attributed to factors such as environmental degradation, population mobility, and cultural practices that facilitate virus transmission, alongside challenges in healthcare infrastructure and response measures that hinder effective containment. The increasing incidence of Ebola outbreaks is driving greater demand for Inmazeb as the need for effective treatment options intensifies in response to the rising number of infections and the urgency to provide timely care to affected populations. For instance, in May 2024, according to a report published by the U.S. Centers for Disease Control and Prevention (CDC), a US-based federal agency, five out of the six outbreaks were linked to the Sudan ebolavirus species. The outbreak was declared over on January 2023, after recording 142 confirmed cases (plus 22 probable cases) and 55 confirmed fatalities. Therefore, the increasing incidence of Ebola outbreaks is driving the growth of the inmazeb industry. An increase in investments in healthcare infrastructure is expected to propel the growth of the inmazeb market going forward. Healthcare infrastructure refers to the physical and organizational structures, facilities, systems, and workforce that collectively support the delivery of healthcare services and promote public health. Increasing investments in healthcare infrastructure are driven by the need to enhance service delivery, improve health outcomes, and address the challenges highlighted by the pandemic. Growing investments in healthcare infrastructure are enhancing the distribution and accessibility of Inmazeb, the first FDA-approved treatment for Ebola, ensuring it reaches affected populations swiftly during outbreaks. For instance, in June 2025, according to the HM Treasury, a UK-based government agency reported that from 2023–24 to 2029–30, DHSC’s annual capital budget will rise by £2.3 billion in real terms (a £4 billion cash increase) to support investments in NHS technology, hospitals, and primary care. This will create the largest-ever health capital budget, representing a 20%+ real-terms increase by the end of the spending review period. Therefore, the increasing investments in healthcare infrastructure are driving the growth of the inmazeb industry. The expansion of drug access programs is expected to propel the growth of the inmazeb market going forward. Drug access programs allow patients with serious or life-threatening conditions to access investigational medications or treatments not yet approved for general use, often outside of clinical trial settings, to address urgent medical needs when no satisfactory alternative therapies are available. The expansion of drug access programs is driven by the need to provide patients with serious or life-threatening conditions access to investigational treatments when no satisfactory alternative therapies are available, address urgent medical needs, and bridge the gap between drug development and regulatory approval processes. The expansion of drug access programs enhances the availability of inmates, as these initiatives facilitate access to this critical treatment for patients with Ebola virus infection, addressing urgent medical needs during outbreaks and improving patient outcomes. For instance, in May 2024, according to the Department of Health and Social Care (DHSC), a UK-based governmental department, naloxone access and invest $670 million in treatment between 2022 and 2025 aims to prevent 1,000 drug-related deaths in England by 2025. Therefore, the expansion of drug access programs is driving the growth of the inmazeb industry.

Key Players In The Global Inmazeb Market

Major companies operating in the inmazeb market are Regeneron Pharmaceuticals Inc.

What Defines the Inmazeb Market?

The inmazeb market consists of sales of atoltivimab, maftivimab, and odesivimab-ebgn. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Inmazeb Market Report 2026?

The inmazeb market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the inmazeb industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.